Grifols will invest 190 million in Catalonia 2020 – Pysn People and Society News

News of Spain

Grifols draws its future in five years. The Catalan multinational is in the final phase of construction of a purification plant plasma-derived blood in Parets del Valles, which has poured 55 million euros, but already projected A new battery investment 2020 looking not only in Catalonia but mainly in the United States.

The plan of the multinational presiding Victor Grifols Roura includes an investment of 1,200 million euros in the next five years, and 81 % will fuel the growth of plants abroad, especially in the US market, but also in Dublin. The remaining 19%, the equivalent of 228 million will be invested in Spain, and Catalonia is the main destination, with 192 million until 2020.

Investment in Paredes del Vallés be realized in the new purification plant alpha-1 protein that must be in place in early 2018, as well as operational improvements in other industrial facilities. It will also build a new factory Diagnostics Division , dedicated to the production of medical devices, where some 10 million euros will be invested.

<- Easy Plugin for AdSense V8.67 ->

the branch business Grifols hospitals, mainly concentrated in Murcia, will receive 36 million new plan, approximately, explained the company. These facilities produce intravenous blood collection bags and solutions, among other products.

USA, the big focus of growth

75% of revenues Grifols are linked to its main activity: fractionation of blood plasma to extract proteins that, once purified, they become drugs used to treat illnesses ranging from hemophilia until respiratory failure or Alzheimer’s. This division, Bioscience, is the main focus of investment, and the US, the Mecca of this growth.

In the US market, Grifols has a network of more than 160 points extracting plasma blood, as the law allows this extraction technique paid to donors. The company expects 300 million investment plan intended to expand this network. A part of the growth will come from exercising the right to purchase the remaining 51% of the company Ibbi, a provider of private plasma with 23 points extraction in the country.

In the hospital industry, Grifols also wants to break strongly in the US. To do this, Kiro trust the robot, which has developed in joint venture with a Basque company Arrasate. It is a machine for preparing solutions and mixtures for cancer treatments already being marketed at a price that is around one million euros each, said Victor Grifols in a meeting with reporters Wednesday.

Source Ara.cat